

## CURRICULUM VITAE



### PERSONAL INFORMATION

Name – Last Name	<b>LOGROSCINO GIANCARLO</b>
Institutional Address 1	CENTER FOR NEURODEGENERATIVE DISEASES AND THE AGING BRAIN UNIVERSITY OF BARI “ALDO MORO” AT AZIENDA OSPEDALIERA “CARD G. PANICO” VIA S. PIO X, 4 73039 TRICASE
Institutional Address 2	UNIVERSITY OF BARI “ALDO MORO” FACOLTÀ DI MEDICINA E CHIRURGIA DEPARTMENT OF BASIC MEDICINE SCIENCE, NEUROSCIENCE AND SENSE ORGANS P.ZZA GIULIO CESARE- 70100 BARI
Phone	0039 0833 773904
Fax	0039 08331830670
E-mail address	<a href="mailto:giancarlo.logroscino@uniba.it">giancarlo.logroscino@uniba.it</a>
Nationality	Italian

### WORKING EXPERIENCE

---

From 6 February 2012	<b>NEUROLOGY AND NEURODEGENERATIVE DISEASES DEPARTMENT</b> CENTER FOR NEURODEGENERATIVE DISEASES AND THE AGING BRAIN. UNIVERSITY OF BARI “ALDO MORO” AT AZIENDA OSPEDALIERA “CARD G. PANICO”
Type of Activity	Research Clinical Teaching
From 2017	<b>FULL PROFESSOR</b> SSD MED/26 NEUROLOGY University of Bari “Aldo Moro” – Faculty of Medicine, University of Bari
Type of Activity	Research Clinical Teaching
From October 2020	Director of of Residency Program in Neurology  University of Bari “Aldo Moro” – Faculty of Medicine, University of Bari
Type of Activity	Research Clinical Teaching
From 2007 to 2017	<b>ASSOCIATE PROFESSOR</b> SSD MED/26 NEUROLOGY University of Bari “Aldo Moro” – Faculty of Medicine, University of Bari
Type of Activity	Research Clinical Teaching
From 2002 to 2007	<b>ASSOCIATE PROFESSOR</b> HSPH Harvard University Boston, MA US
Type of Activity	Research

## Teaching

From 2004 to 2008

Type of Activity

**ADJUNCT**  
Division of Aging  
Harvard School of Medicine, Harvard University Boston, MA US  
Research

From 1997 to 2002

Type of Activity

**Consultant Neurologist (dirigente I clinico livello)**  
Regional Hospital Miulli. Acquaviva delle Fonti (BA)  
Clinical  
Teaching  
Research

From 1992 to 1997

Type of Activity

**Researcher**  
Sergievsky Center. Department of Neurology. Columbia University, New York, NY USA  
Research  
Clinical  
Teaching

From 1986 to 1993

Type of Activity

**Consultant in Neurology (Neurology Clinical Assistant)**  
Neurology Division. Regional Hospital Miulli. Acquaviva delle Fonti (BA)  
Research  
Clinical  
Teaching

From 1983 to 1986

Type of Activity

**Emergency medical Service**  
Santeramo in Colle/ Gioia del Colle  
Clinical

From 1981 to 1982

Type of Activity

**Medical Officer**  
IX Battaglione GRAPECAM Foggia  
Clinical

## EDUCATION AND TRAINING

**2000**

Institution

**Post-Graduate Training.**  
Teaching Epidemiology. Summer Graduate Session.  
Department of Epidemiology  
Johns Hopkins University, Baltimore

**2002**

Institution

**Post-Graduate Training**  
Genetic Analysis Complex Human Disease. Center for Human Genetics. Duke University (NC)

**1999**

Institution

**Post-Graduate Training.**  
Genetic Epidemiology and Molecular biology for Epidemiologic Studies  
Institute of Genetic Epidemiology  
Erasmus University, Rotterdam

**1997**

Institution

**Doctorate of Philosophy in Epidemiology (PhD)**  
Graduate School of Arts and Sciences Columbia University, New York, NY USA

<b>1996</b>	<b>Post-Graduate Training.</b>
Institution	Linkage Analysis Department of Genetics and Development Columbia University
<b>1996</b>	<b>Master of Philosophy (Mphyl) in Epidemiology</b>
Institution	Graduate School of Arts and Sciences Columbia University, New York, NY USA
<b>1992</b>	<b>Post-Graduate Training.</b>
Institution	Epidemiologic methods: introductory course Summer Graduate Session Department of Epidemiology University of Michigan, Ann Arbor, MI.
<b>1993</b>	<b>Post-Graduate Training.</b>
Institution	Study Design. Clinical trials. Summer Graduate Session Department of Epidemiology Johns Hopkins University, Baltimore, MD.
<b>1994</b>	<b>Master of Science in Epidemiology (MS)</b>
Institution	School of Public Health Columbia University, New York, NY USA
<b>1987</b>	<b>Diploma in Clinical Neurochemistry</b>
Institution	Institute of Neurology. Faculty of Medicine, University of Bari
<b>1986</b>	<b>Diploma in Neurochemistry and Neurophysiology</b>
Institution	Institute of Neurology. Faculty of Medicine, University of Bari
<b>1984-1986</b>	<b>Research Fellow</b>
Institution	Department of Neurology. School of Medicine, University of Bari.
<b>1984</b>	<b>Specialization in Neurology</b>
Institution	Institute of Neurology. Faculty of Medicine, University of Bari
<b>1980</b>	<b>Degree in Medicine, University of Bari</b>
Institution	Institute of Neurology. Faculty of Medicine, University of Bari

**PERSONAL SKILLS**

MOTHER TONGUE

**Italian**

OTHER LANGUAGES

	<b>English</b>	<b>Franch</b>	<b>Spanish</b>
• Reading	Excellent	Good	Good
• Writing	Excellent	Good	Good
• Speaking	Excellent	Excellent	Excellent

SKILL AND SOCIAL ORGANIZATION

In regard to research, he worked with interdisciplinary national and international working groups and has played a coordinating role.

## Research Activity

Giancarlo Logroscino, MD PhD is the director of the Neurodegenerative Diseases Unit of The University of Bari and Chair of the Department of Clinical Research in Neurology at Pia Fondazione Panico in Tricase (LE).

He is full Professor of Neurology at University of Bari.

He has been trained in Neurology (University of Bari) and Epidemiology (PhD, Columbia University NYC). He has been associate professor of epidemiology and neurology at Harvard University (2002-2008).

His primary research interests are natural history of neurodegenerative diseases and environmental risk factors for neurodegenerative diseases related to aging. He has conducted studies on Parkinson's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Fronto-temporal dementia, Lewy Body Diseases both in clinical settings and in population based settings.

He is leading projects and studies in Europe and outside Europe.

He has studied the role of dietary factors and iron/iron (metals) metabolism in Parkinson's disease and Alzheimer's disease.

He has established one of the first population-based registries of Amyotrophic Lateral Sclerosis in the world, (SLAP) based in Apulia, Southern Italy. He is a member of the steering committee of EURALS, the European project on descriptive and analytic factors of ALS. He is part of EUROMOTOR consortium. He is the co-PI of a Center for Disease Controls (CDC) funded, project to study ALS and cognitive impairment in ALS in South America.

He has established a population based registry for Rare Neurodegenerative Diseases in Puglia (SLAP\_Dem\_Puglia\_Registry). A similar project has been recently launched in Albania, Kosovo and Montenegro (Balkan area) and Cambodia.

He is focusing on the aging brain and risk/protective factors for cognitive decline and longevity with data from prospective cohorts both in the US and Europe.

He is the PI of the Great Age study, a population-based study on aging, frailty neurodegeneration and diet in Castellana Grotte (BA), recently awarded by a special grant for aging research. In this study eight research groups are studying the complexities of the aging process.

He is working on methodological issues on studies of neurodegenerative diseases. In this context is a member of MELODEM (methods in longitudinal studies of dementia)

He is part of the of the Global Burden of Diseases (GBD) and of the task force on neurology of the Global Burden of Disease (GBD) founded by World Bank and Bill and Melissa Gates Foundation.

He is part of the Global Burden of Disease Italy the group to establish national task force of the GBD in Italy, similarly to other countries like US, China, UK, Mexico and Saudi Arabia.

In the Center for Neurodegenerative diseases of the University of Bari in Tricase patients are diagnosed and followed with advanced criteria and several clinical trials in the early phase are conducted with the support of international agencies and pharma companies.

He has been a member of the Chairs of Section Committee (COE) of the American Academy of Neurology (AAN) (2012-16), past chair of the neuroepidemiology section of the AAN and member of the Applied Research Committee (ARC) of the World Federation of Neurology (WFN).

He is member of the Scientific Committee of the American Brain Foundation (ABF), the largest private foundation for neurological research in the world.

He has been President of the Neuroepidemiological Italian Association (NEP) and member of the steering committee of the Italian Neurological Association (SIN) (from 2014 to 2018).

He has been the Convenor for the Neuroepidemiology Section of the last meetings (Wien, Austria 2013) (Santiago, Chile 2015) of the World Federation of Neurology Congress.

He has published more than 300 papers on highly impact factor journals including BMJ, JAMA, Lancet, Lancet Neurology, Annals of Neurology, Neurology and Brain.

He is the associated editor of the journal Neuroepidemiology, Karger, Basel and of the reviewers for about thirty journals including New England Journal of Medicine, Lancet, JAMA, BMJ.

He is co-editor of the Textbook of Neuroepidemiology for Oxford University Press (in press. Editors: C. Brayne, V. Feigin, L. Launer, G. Logroscino).

He is Principal Investigator for the following CTR:

- 2016-2019. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease. Sponsor BIOGEN.;
- 2018-2019 A Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of mtau9937a in patients with prodromal to mild alzheimer's disease. Sponsor GENENTECH.
- 2017-2018 A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB). Sponsor: AXOVANT.
- 2018-2019 The effects of RNS60 on ALS biomarkers. Sponsor Istituto Mario Negri – Milano.
- 2019 Ruolo Della Citicolina Nella Terapia di Supporto Nella Malattia di Parkinson. Sponsor GB PHARMA/ PIAM Farmaceutici S.p.A.
- BAN2401 A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

## SELECTION OF MORE THAN 280 PUBLICATIONS

1. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. *Ann Neurol* 1996;39:89-94.
2. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Loiacono N, Cote L, Mayeux R. Altered systemic iron metabolism in Parkinson's disease. *Neurology* 1997;49(3):714-7.
3. Schofield PW, Logroscino G, Andrews HF, Albert S, Stern Y. An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia. *Neurology* 1997;49(1):30-7.
4. Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, Cote L, Mayeux R. Environmental risk factors for Parkinson's disease in an urban multiethnic community. *Neurology* 1998;50(1):279-81.
5. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. *Neurology* 1998;50(3):735-41.

6. Marder K, Logroscino G, Tang MX, Graziano J, Cote L, Louis E, Alfaro B, Mejia H, Slavkovich V, Mayeux R. Systemic iron metabolism and mortality from Parkinson's disease. *Neurology* 1998;50(4):1138-40
7. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. *Epilepsia* 1997;38(12):1344-9.
8. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, Cote L, Mayeux R. Dietary iron, animal fats, and risk of Parkinson's disease. *Mov Disord* 1998;13 Suppl 1:13-6.
9. Hesdorffer D, Logroscino G, Cascino GD, Annegers JF, Hauser WA. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. *Ann Neurol* 1998;44: 908-12.
10. Cascino GD, Hesdorffer D, Logroscino G, Hauser WA. Morbidity of non febrile status epilepticus in Rochester, Minnesota, 1965-1984. *Epilepsia* 1998;39(8):829-32.
11. Cascino GD, Hesdorffer D, Logroscino G, Hauser WA. Treatment of non-febrile status epilepticus in Rochester, Minnesota, 1965-1984. *Mayo Clinic Proceedings Mayo Clin Proc* 2001;76(1):39-41.
12. Defazio G, Livrea P, De Salvia R, Manobianca G, Coviello V, Anaclerio D, Guerra V, Martino D, Valluzzi F, Liguori R, Logroscino G. Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy. *Neurology* 2001;56(11):1579-81.
13. Oliveri RL, Zappia M, Annesi G, Bosco D, Annesi F, Spadafora P, Pasqua AA, Tomaino C, Nicoletti G, Pirritano D, Labate A, Gambardella A, Logroscino G, Manobianca G, Epifanio A, Morgante L, Savettieri G, Quattrone A. The parkin gene is not involved in late-onset Parkinson's disease. *Neurology* 2001;57(2):359-62.
14. Oliveri RL, Zappia M, Annesi G, Annesi F, Spadafora P, Pasqua AA, Tomaino C, Nicoletti G, Bosco D, Messina D, Logroscino G, Manobianca G, Epifanio A, Morgante L, Savettieri G, Quattrone A. The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease. *Neurol Sci* 2001;22(1):73-4.
15. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. *Epilepsia*. 2001;42(8):1031-5.
16. Beghi E, Logroscino G, Micheli A, Millul A, Perini M, Riva R, Salmoiraghi F, Vitelli E. Validity of hospital discharge diagnoses for the assessment of the prevalence and incidence of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2001;2(2):99-104.
17. Logroscino G, Hesdorffer DC, Cascino GD, Annegers JF, Bagiella E, Hauser WA. Long-term mortality after a first episode of status epilepticus. *Neurology* 2002;58(4):537-41.
18. Beghi E, Balzarini C, Bogliun G, Logroscino G, Manfredi L, Mazzini L, Micheli A, Millul A, Poloni M, Riva R, Salmoiraghi F, Tonini C, Vitelli E. The Italian ALS Study Group. Reliability of the El Escorial diagnostic criteria for amyotrophic lateral sclerosis. *Neuroepidemiology* 2002 ;21(6):265-70.
19. Marder K, Logroscino G. The ever-stimulating association of smoking and coffee and Parkinson's disease. *Ann Neurol* 2002;52(3):261-2.
20. Logroscino G, Livrea P, Anaclerio D, Aniello MS, Benedetto G, Cazzato G, Giampietro L, Manobianca G, Marra M, Martino D, Pannarale P, Pulimeno R, Santamato V, Defazio G. Agreement among neurologists on the clinical diagnosis of dystonia at different body sites. *Journal of Neurology, Neurosurgery & Psychiatry* 2003;74(3):348-50.
21. Defazio G, Martino D, Aniello MS, Masi G, Logroscino G, Manobianca G, Lastilla M, Livrea P. Influence of age on the association between primary hemifacial spasm and arterial hypertension. *J Neurol Neurosurg Psychiatry* 2003;74:979-81.
22. Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, Girlanda P, Le Pira F, Liguori M, Logroscino G, Lugaresi A, Nocentini U, Reggio A, Salemi G, Serra P, Tedeschi G, Toma L, Trojano M, Valentino P, Quattrone A. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. *J Neurol*. 2003; 250(9): 1094-8.
23. Logroscino G., Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. *BMJ*. 2004; 328(7439):548.
24. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G for the SLAP registry. Signs and symptoms at diagnosis of Amyotrophic Lateral Sclerosis: a population-based study in Southern Italy. *European Journal of Neurology*. 2006 Jul ;13(7):789-92
25. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G; the SLAP registry. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. *J Neurol Sci*. 2006; 250(1-2):45-9.

26. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, Swingler R, Traynor BJ; on behalf of the EURALS Consortium. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, Swingler R, Traynor BJ; on behalf of the EURALS Consortium. The epidemiology of ALS and the role of population-based registries. *Biochim Biophys Acta*. 2006;1762(11-12):1150-7.
27. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G; SLALOM Group. Incidence of ALS in Lombardy, Italy. *Neurology*. 2007 ;68(2):141-5
28. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G; SLAP registry et al. Riluzole and ALS survival: a population-based study in Southern Italy. *Eur J Neurol* 2007; 14:262-268
29. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G. ALS multidisciplinary clinic and survival : Results from a population-based study in Southern Italy. *J Neurol*. 2007; PMID: 17431705 [PubMed - as supplied by publisher]
30. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone I, Lamberti P, Serlenga L, Logroscino G. ALS Prognosis is heterogeneous across different phenotypes: a population-based study. *J Neurol Neurosurg Psychiatry*. 2007 Jun 5; [Epub ahead of print]
31. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G; SLAP Registry. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. *J Neurol Neurosurg Psychiatry*. 2008 Jan;79(1):33-7. Epub 2007 Jun 5.
32. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone I, Lamberti P, Serlenga L, Logroscino G. Elevated plasma homocysteine levels in patients with Amyotrophic Lateral Sclerosis. *Neurology*, 2008 15;70(3):222-5.
33. ZOCCOLELLA S, BENDOTTI C, BEGHI E, LOGROSCINO G. Homocysteine levels and amyotrophic lateral sclerosis: A possible link. *AMYOTROPHIC LATERAL SCLEROSIS*, vol. 11(1-2), p. 140 (2010)
34. BEGHI E, LOGROSCINO G, CHIÒ A, HARDIMAN O, MILLUL A, MITCHELL D, SWINGLER R, TRAYNOR BJ (2010). Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. *AMYOTROPHIC LATERAL SCLEROSIS*, vol. 11(3):, p. 289-292, ISSN: 1748-2968 –( 2010)
35. ZOCCOLELLA S, SIMONE IL, CAPOZZO R, TORTELLI R, LEO A, D'ERRICO E, LOGROSCINO G . An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis . *JOURNAL OF NEUROLOGY*, vol. 258, p. 238-243, ISSN: 0340-5354 (2011)
36. PANZA F, FRISARDI V, IMBIMBO BP, SERIPA D, PARIS F, SANTAMATO A, D'ONOFRIO G, LOGROSCINO G, PILOTTO A, SOLFRIZZI V. Anti- $\beta$ -amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. *Curr Alzheimer Res*. Dec;8(8):808-17. Review.(2011)
37. SIMONE IL, RUGGIERI M, TORTELLI R, CECI E, D'ERRICO E, LEO A, ZOCCOLELLA S, MASTRAPASQUA M, CAPOZZO R, LIVREA P, LOGROSCINO G . Serum N-acetylaspartate level in amyotrophic lateral sclerosis. . *ARCHIVES OF NEUROLOGY* (2011)
38. BEGHI E, PUPILLO E, MESSINA P, GIUSSANI G, CHIÒ A, ZOCCOLELLA S, MOGLIA C, CORBO M, LOGROSCINO G; EURALS Group. Coffee and amyotrophic lateral sclerosis: a possible preventive role. *Am J Epidemiol*. Nov 1;174(9):1002-8. doi: 10.1093/aje/kwr229. Epub 2011 Sep 26. Oct doi: 10.1016/j.neuron.2011.09.010. Epub 2011 Sep 21. 20;72(2):257-68.
39. LOGROSCINO G. Amyotrophic lateral sclerosis descriptive studies: not only rates and frequencies. *Neuroepidemiology*. 41(1):62-3. doi: 10.1159/000350016. Epub 2013 May 25
40. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. *Expert Rev Clin Immunol*. 2014 Mar;10(3):405-19. doi: 10.1586/1744666X.2014.883921. Epub 2014 Feb 4. Review. PubMed PMID: 24490853
41. Ferrari R, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol*. 2014 Jul;13(7):686-99.
42. Logroscino G, Ludolph A. Amyotrophic lateral sclerosis: new ideas from cancer. *Lancet Neurol*. 2014 Nov;13(11):1067-8. doi: 10.1016/S1474-4422(14)70177-2. Epub 2014 Oct 7. PubMed PMID (2014)
43. Pupillo E, Messina P, Logroscino G, Beghi E. Long-term survival in amyotrophic lateral sclerosis: a population-based study. *Ann Neurol*. 2014;75(2):287-97.
44. Johnson JO, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat Neurosci*. 2014 May;17(5):664-6. doi: 10.1038/nn.3688. Epub 2014 Mar 30. PubMed PMID: 24686783; PubMed Central PMCID: PMC4000579
45. Tortelli R, Copetti M, Ruggieri M, Cortese R, Capozzo R, Leo A, D'Errico E, Mastrapasqua M, Zoccolella S, Pellegrini F, Simone IL, Logroscino G. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. *Eur J Neurol*. Apr 22. doi: 10.1111/ene.12421 (2014)
46. Panza F, Solfrizzi V, Logroscino G. Age-related hearing impairment—a risk factor and frailty marker for dementia and AD. *Nat. Rev. Neurol*. 2015 Advance online publication .

47 Palmer SC, et al. COGNITIVE-HD Study Investigators. COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis. *BMJ Open*. 2015 Dec9;5(12):e009328. doi: 10.1136/bmjopen-2015-009328. PubMed PMID: 26656022; PubMed Central PMCID: PMC4679889.

48 Tortelli R, Copetti M, Arcuti S, Tursi M, Iurillo A, Barulli MR, Cortese R, Capozzo R, D'Errico E, Marin B, Simone IL, Logroscino G. Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). *J Neurol*. 2016 Feb;263(2):316-21. doi: 10.1007/s00415-015-7981-3. Epub 2015 Nov 20. PubMed PMID: 26588919.

49 Marin B, Couratier P, Arcuti S, Copetti M, Fontana A, Nicol M, Raymondeau M, Logroscino G, Preux PM. Stratification of ALS patients' survival: a population-based study. *J Neurol*. 2016 Jan;263(1):100-11. doi:10.1007/s00415-015-7940-z. Epub 2015 Oct 30. PubMed PMID: 26518423.

50 Marin B, Bianchi E, Pupillo E, Lunetta C, Tremolizzo L, Logroscino G, Chiò A, Preux PM, Beghi E. Non-self-sufficiency as a primary outcome measure in ALS trials. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015 Jan-Feb;17(1-2):77-84. doi: 10.3109/21678421.2015.1074704. Epub 2015 Oct 16. PubMed PMID: 26470831.

51 Marin B, Logroscino G, Boumédiène F, Labrunie A, Couratier P, Babron MC, Leutenegger AL, Preux PM, Beghi E. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. *Eur J Epidemiol*. 2016 Mar;31(3):229-45. doi: 10.1007/s10654-015-0090-x. Epub 2015 Oct 12. Review. PubMed PMID: 26458931.

52 Solfrizzi V, Panza F, Imbimbo BP, D'Introno A, Galluzzo L, Gandin C, Misciagna G, Guerra V, Osella A, Baldereschi M, Di Carlo A, Inzitari D, Seripa D, Pilotto A, Sabbà C, Logroscino G, Scafato E; Italian Longitudinal Study on Aging Working Group. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. *J Alzheimers Dis*. 2015;47(4):889-99. doi: 10.3233/JAD-150333. PubMed PMID: 26401769.

53 Panza F, Seripa D, Solfrizzi V, Tortelli R, Greco A, Pilotto A, Logroscino G. Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. *J Alzheimers Dis*. 2015;47(4):793-813. doi: 10.3233/JAD-150358. PubMed PMID: 26401761.

54 Bennett DA, Brayne C, Feigin VL, Barker-Collo S, Brainin M, Davis D, Gallo V, Jetté N, Karch A, Kurtzke JF, Lavados PM, Logroscino G, Nagel G, Preux PM, Rothwell PM, Svenson LW. Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. *Neuroepidemiology*. 2015;45(2):113-37. doi: 10.1159/000439132. Epub 2015 Sep 22. PubMed PMID: 26390430.

55 Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Santamato A, Lozupone M, Prete C, Greco A, Pilotto A, Logroscino G. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. *Expert Opin Pharmacother*. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21. PubMed PMID: 26389682.

56 Barulli MR, Fontana A, Panza F, Copetti M, Bruno S, Tursi M, Iurillo A, Tortelli R, Capozzo R, Simone IL, Logroscino G. Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. *BMJ Open*. 2015 Sep 3;5(9):e007069. doi: 10.1136/bmjopen-2014-007069. PubMed PMID: 26338835; PubMed Central PMCID: PMC4563243.

56 Benedetti MD, Pugliatti M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Galeotti F, Massari M, Santuccio C, Raschetti R; ITANG Study Group. A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. *Neuroepidemiology*. 2015;45(2):90-9. doi: 10.1159/000438752. Epub 2015 Aug 29. PubMed PMID: 26329724.

57 Logroscino G. Motor neuron disease: Are diabetes and amyotrophic lateral sclerosis related? *Nat Rev Neurol*. 2015 Sep;11(9):488-90. doi: 10.1038/nrneurol.2015.145. Epub 2015 Aug 18. PubMed PMID: 26281962.

58 Tortelli R, Copetti M, Panza F, Fontana A, Cortese R, Capozzo R, Introna A, D'Errico E, Zoccollella S, Arcuti S, Seripa D, Simone IL, Logroscino G. Time to generalization and prediction of survival in patients with amyotrophic lateralsclerosis: a retrospective observational study. *Eur J Neurol*. 2016 Mar 25. doi: 10.1111/ene.12994. [Epub ahead of print] PubMed PMID: 27016147.

59 Babiloni C, et al. Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. *Front Neurosci*. 2016 Feb 23;10:47. doi: 10.3389/fnins.2016.00047. eCollection 2016. PubMed PMID: 26941594; PubMed Central PMCID: PMC4763025.

60 Marin B, Arcuti S, Jesus P, Logroscino G, Copetti M, Fontana A, Nicol M, Raymondeau M, Desport JC, Preux PM, Couratier P; French register of ALS in Limousin (FRALim). Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis Is Related to Weight Loss at Diagnosis. *Neurodegener Dis*. 2016;16(3-4):225-34. doi: 10.1159/000442444. Epub 2016 Feb 12. PubMed PMID: 26866503.

61 Marin B, Beghi E, Vial C, Bernard E, Lautrette G, Clavelou P, Guy N, Lemasson G, Debruxelles S, Cintas P, Antoine JC, Camdessanche JP, Logroscino G, Preux PM, Couratier P; EURECAL consortium. Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres. *Eur J Neurol*. 2016 Apr;23(4):787-95. doi: 10.1111/ene.12941. Epub 2016 Feb 1. PubMed PMID: 26833536.

62 Seripa D, Solfrizzi V, Imbimbo BP, Daniele A, Santamato A, Lozupone M, Zuliani G, Greco A, Logroscino G, Panza F. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthionium. *Expert Rev Neurother*. 2016 Mar;16(3):259-77. doi: 10.1586/14737175.2016.1140039. PubMed PMID: 26822031.

63 Veneziani F, et al. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail? *Int Psychogeriatr*. 2016 Jan 28:1-14. [Epub



ahead of print] PubMed PMID: 26817511.

64 Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Santamato A, Lozupone M, Capozzo R, Prete C, Pilotto A, Greco A, Logroscino G. Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy? *Expert Opin Pharmacother*. 2016Mar;17(4):457-61. doi: 10.1517/14656566.2016.1146686. Epub 2016 Feb 15. PubMed PMID: 26809554.

95 Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. *Neurology*. 2016 Feb 9;86(6):566-76. doi: 10.1212/WNL.0000000000002350. Epub 2016 Jan 13. Review. PubMed PMID: 26764028.

96 Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. *Nat Rev Dis Primers*. 2017 Oct 5;3:17071. doi: 10.1038/nrdp.2017.71. Review. Erratum in: *Nat Rev Dis Primers*. 2017 Oct 20;3:17085. PubMed PMID: 28980624.

"I, the undersigned Giancarlo Logroscino is aware that, under Article 26 of Law 15/68, false statements, falsified acts and use of false acts are punishable under the Penal Code and special laws. In addition, the / the undersigned / or authorizes the processing of personal data, as provided by Law 196/03. "

**Bari, 31/12/2020**

A handwritten signature in black ink, reading "Giancarlo Logroscino". The signature is written in a cursive style and is underlined with a single horizontal stroke.